| Objective: Osteoporosis is an important health problem for postmenopausal women in China.However,at present,the compliance of zoledronic acid in the treatment of postmenopausal women with osteoporosis is insufficient,and the understanding of the need for continuous treatment of osteoporosis is insufficient.Therefore,this study explored the clinical efficacy of zoledronic acid in the treatment of postmenopausal osteoporosis,in order to clarify the necessity of standardized anti osteoporosis treatment.Methods: A total of 90 postmenopausal women with osteoporosis treated in the First Affiliated Hospital of China Medical University from October to December 2018 were randomly selected.All patients were observed until December 2020.The patients were divided into three groups according to the frequency of zoledronic acid use.Group Z1: on the basis of regular oral calcium carbonate D3 granules,30 patients only used zoledronic acid intravenous drip once;Z2 group: on the basis of regular oral calcium carbonate D3 granules,30 patients used zoledronic acid intravenous injection twice;Z3 group: on the basis of regular oral administration of calcium carbonate D3 granules,30 patients were given zoledronic acid intravenous injection three times.The changes of bone mineral density,pain score,new fracture and quality of life were compared among the three groups before the first application of zoledronic acid(i.e.the first application),after the first application,after the second application and after the third application.Results: There was no significant difference in the changes of BMD,pain score,new fracture and quality of life among the three groups before and after the first application of zoledronic acid(P > 0.05)The difference of quality of life was statistically significant(P < 0.05).Conclusion: 1.Zoledronic acid can improve the bone mineral density of lumbar spine and hip joint in postmenopausal osteoporosis patients,and reduce the new fractures of patients.2.Patients who use zoledronic acid three times can better relieve the pain symptoms and improve the quality of life of patients than patients who only use zoledronic acid once or twice. |